natgillin/translations-raw huggingface dataset:
The process of claim 1, wherein, in the step b), the ratio of the residue or pulverized higher plants or fungi obtained in step a) to the amount of the acid solution is 5/1 to 1/5. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što je, u koraku 2), omjer između ostatka ili više biljke ili gljive smrvljene u prah dobivene u koraku 1) i količine otopine kiseline 5/1-1/5.
An electrically heated smoking system according to any of claims 1 to 7, wherein the electrically insulating substrate is tubular and the one or more electrically conductive tracks are on the outside of the tubular electrically insulating substrate. 
Električno grijani sustav za pušenje u skladu s patentnim zahtjevom 1, 2 1li 3, naznačen time što se jedna ili više električno vodljivih tračnica (203) nalazi s vanjske strane cijevi od električno izolirajuće podloge (201).
The antibody drug conjugate according to claim 1, wherein the antibody comprises a VH region comprising an amino acid sequence of SEQ ID NO: 5 and a VL region comprising an amino acid sequence of SEQ ID NO: 45. 
Konjugat protutijela s lijekom prema patentnom zahtjevu 1, naznačen time, da protutijelo obuhvaća VH područje koje sadrži aminokiselinsku sekvencu SEQ ID NO:5 1 VL područje koje sadrži aminokiselinsku sekvencu SEQ ID NO:45.
0.17 Total Capsule Weight Pharmaceutical dosage form according to claim 4 in form of a soft gelatin capsule containing 125 mg of active substance free base equivalent, selected from the following compositions A, B and C: 
Farmaceutski dozni oblik prema bilo kojem od zahtjeva 1 do 3, naznačen time, da je dozni oblik prikladan za 5. = Farmaceutski dozni oblik prema zahtjevu 4, naznačen time, da je u obliku mekane želatinske kapsule koja sadrži 50 mg djelatne tvari, ekvivalenta slobodne baze, koji je odabran od sljedećih sastava A, B 1 C:
A method of treating a psychiatric disorder selected from the group consisting of bipolar disorder, schizophrenia, and generalized anxiety disorder, comprising administering to a patient in need thereof an effective amount of a compound according to claim 1, or pharmaceutically acceptable salt thereof. 
10. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 7, ili njegova farmaceutski prihvatljiva sol, naznačen time što je namijenjen upotrebi u liječenju psihijatrijskog poremećaja koji se bira iz skupine koju čine bipolarni poremećaj, shizofrenija, te generalizirani anksiozni poremećaj.
(iii)mixing the hydrophilic solvent with the hydrophobic solvent under suitable conditions to form the composition comprising a polyaphron dispersion; wherein the hydrophilic solvent and/or the hydrophobic solvent comprises a surfactant; and wherein the hydrophilic solvent and/or the hydrophobic solvent optionally comprises a pharmaceutically active agent. 
(iii) miješanje hidrofilnog otapala s hidrofobnim otapalom u prikladnim uvjetima kako bi se dobio pripravak koji sadrži poliafronsku disperziju; pri čemu hidrofilno otapalo i/ili hidrofobno otapalo sadrži surfaktant; i pri čemu hidrofilno otapalo i/ili hidrofobno otapalo opcionalno sadrži farmaceutski aktivnu tvar.
A combination according to claim 4 wherein the long-acting B2 agonist is salmeterol. 
Kombinacija sukladno patentnom zahtjevu 4, naznačena time, da je kortikosteroid mometazon furoat.
Systems of controlled and/or programmed release suitable for the present invention are described in EP 1183014, GB 2245492 and EP572942, which are also incorporated herein by reference. 
Odgovarajući sustavi kontroliranog i/ili programiranog otpuštanja za ovaj izum opisani su u EP 1183014, GB 2245492 i EP 572942.
The compound of claim 1, wherein the antibiotic agents are selected from the group consisting of B- Lactam antibiotics, tetracyclines, macrolide antibiotics, aminoglycosides, quinolones, cyclic peptides, lincosamides, and sulfa antibiotics. 
Spoj za primjenu prema patentnom zahtjevu 1, gdje je terapijski agens antibiotski agens izabran iz grupe koja se sastoji od B-laktamskih antibiotika, tetraciklina, makrolidnih antibiotika, aminoglikozida, hinolona, cikličnih peptida, linkozamida, i sulfa antibiotika.
Also described is the use of the hydrophobised ground calcium carbonate and/or the hydrophobised precipitated calcium carbonate for reducing the amount of pitch in an aqueous medium generated in a papermaking or pulping process. Also described is a composite comprising the hydrophobised ground calcium carbonate and/or the hydrophobised precipitated calcium carbonate and pitch. According to one preferred embodiment of the process according to the present invention, the source of ground calcium carbonate (GCC) is selected from marble, chalk, calcite, dolomite, limestone and mixtures thereof and/or the precipitated calcium carbonate (PCC) is selected from one or more of the aragonitic, vateritic and calcitic mineralogical crystal forms. 
HR P20160787 T1 PATENTNI ZAHTJEVI Postupak za smanjenje nepoželjnih tvari u vodenom mediju koje su nastale u postupku proizvodnje papira ili proizvodnje pulpe, naznačen time da sadrži slijedeće korake: a) osiguravanje vodenog medija koji sadrži nepoželjne tvari nastale u postupku proizvodnje papira ili proizvodnje pulpe; b) osiguravanje prirodnog kalcijevog karbonata i/ili taložnog kalcijevog karbonata, pri čemu je izvor prirodnog kalcijevog karbonata (GCC) odabran od mramora, krede, kalcita, dolomita, vapnenca i njihovih smjesa i/ili taložni kalcijev karbonat (PCC) je odabran od jednog ili više od aragonitnih, vateritnih i kalcitnih mineraloških kristalnih oblika;
breaking the adduct of quinine and Compound (C-1) by treating the adduct with HCl to form Compound (C-1) or a pharmaceutically acceptable salt thereof; and 
(h) rastavljanju adukta kinina sa Spojem (C-1) obradom adukta s HCI kako bi se dobilo Spoj (C-1), ili 25 njegovu farmaceutski prihvatljivu sol;
The use of any one of claims 8-9, wherein said dermal micro-organ includes fat tissue. 
Uporaba iz bilo kojeg od patentnih zahtjeva 8 - 9, naznačena time, da navedeni dermalni mikroorgan sadrži masno tkivo.
The component (B) is known. 
(B) spoj fluopiram.
The said air sizing of step d) of the method according to the invention is preferentially a sizing using a sieve and/or a cyclone device. 
Postupak prema jednom od zahtjeva 1 do 25, naznačen time da korak d) razvrstavanja pomoću zraka je razvrstavanje korištenjem uređaja za prosijavanje i/ili ciklonskog uređaja.
At this point the cuff 6 may be positioned to wrap around the walls 16a and 16b of the first appendix 15 of the buttress element 5 of the shell 3, and therefore connected to the same by means of the insertion of the lugs 33 in the sixth holes 34 and in the fourth holes 19a, 19b. 
Na tom mjestu manžeta 6 se može smjestiti na omot oko stijenke 16a 1 16b prvog nastavka 15 potpornog elementa 5 plašta 3, 1 zbog toga se može spojiti s njim stavljanjem umetka 33 u šeste rupice 34 i u četvrte rupice 19a, 19b.
a magnetic induction field of intensity set between 1 Gauss and 70000 Gauss; 
- < magnetsko indukcijsko polje jačine između 1 Gaussa i 70000 Gaussa;
Most preferably the fatty acid esters of the trisaccharides derivates used in such a mixture are the same, such as for example the ester of lauric acid. 
Upotreba u skladu s bilo kojim od patentnih zahtjeva 1-9, naznačena time što su esterske skupine masnih kiselina esteri laurinske kiseline.
Summary: A mutant Pichia pastoris alcohol oxidase 1 (AOX1) promoter of the wild type Pichia pastoris AOX1 promoter (SEQ ID No. 1) comprising at least one mutation selected from the group consisting of: 
Promotor alkoholne oksidaze 1 mutantne Pichia pastoris (AOX1), kao promotor divljeg tipa Pichia pastoris AOX1 (SEQ ID No.1) naznačen time, da sadrži najmanje jednu mutaciju unutar nukleotida 694 do 723 (-260 do -231) od SEQ ID No.1 za visoku ekspresiju pod uvjetima derepresije u odnosu na promotor AOX1 divljeg tipa.
represents a hydrogen atom; and R4 represents a phenyl group which is optionally substituted, a naphthyl group which is optionally substituted, or a thienyl group which is optionally substituted. 
predstavlja atom vodika; a predstavlja skupinu fenila koja je po izboru supstituirana, skupinu naftila koja je po izboru supstituirana, ili skupinu tienila koja je po izboru supstituirana.
The method of claim 17, wherein the CRISPR/Cas system comprises a Cas9 nuclease and a guide RNA comprising a fused crRNA-tracrRNA. 
Postupak sukladno patentnom zahtjevu 15, naznačen time, da nukleazni agens sadrži CRISPR/CAS koji sadrži Cas9 nukleazu i vodeću RNK (gRNK) koja sadrži fuzioniranu crRNK-tracrRNK.
A compound of formula (1): wherein: Q is a single bond, -O-, -S- or -N(R15)- wherein R15 is hydrogen, C1-3alkyl or C2-3alkanoyl or R15 and R1 together with the nitrogen atom to which they are attached form a 4-7 membered saturated ring; 
Spoj formule (1): [image] naznačen time da: Q je jednostruka veza, -O-, -S- ili -N(R15)- pri čemu R15 je vodik, C1-3alkil ili C2-3alkanoil ili R15 i R1 zajedno sa atomom dušika na koji su spojeni tvore 4-7 člani zasićeni prsten;
A pharmaceutical composition comprising an effective amount of at least one compound of formula (I) as defined in anyone of claims 1-11 above, a salt thereof with a pharmaceutically acceptable organic or inorganic acid or base, or an ester prodrug thereof, and at least one inert pharmaceutically acceptable excipient. 
Farmaceutski sastav, naznačen time, da on obuhvaća učinkovitu količinu najmanje jednog spoja formule (1) prema bilo kojem od zahtjeva 1 do 11, njegovu sol s farmaceutski prihvatljivom organskom ili anorganskom kiselinom ili lužinom, ili njegovu estersku prosupstancu, te najmanje jedno inertno farmaceutski prihvatljivo pomoćno sredstvo.
Examples of these methods and the resulting buildings are disclosed in US-A-5,353,562, US-A-4,823,534 and US 5,617,686. 
Primjeri ovih postupaka i građevine iz njih proizašle objavljene su u USA-5,353,562, US-A-4,823,534 1 US 5,617,686.
Providing a feed material; Pressurizing the feed material to a predetermined process pressure of 150 to 400 bar; 
- stlačivanju dovodnog materijala do zadanog tlaka obrade od najmanje 150 bara (15 MPa);
Number of negative charges (Asp+Glu): 141 
(97) Broj objave europskog patenta:
A method for treating pancreatic neuroendocrine tumors, comprising administering to a human subject in need thereof a therapeutically effective amount of 40-O-(2-hydroxyethyl)-rapamycin as a monotherapy and wherein the tumors are advanced tumors after failure of cytotoxic chemotherapy. 
40-O-(2-hidroksietil)-rapamicin za uporabu u obradi invazivnosti neuroendokrinog tumora pankreasa prema zahtjevu 8, naznačen time, da se sprečava širenje metastaza ili se inhibira rast mikrometastaza.
The aqueous agrochemical suspension formulation according to claim 8, wherein the inorganic thickener is at least one kind selected from the group consisting of magnesium aluminium silicate and montmorillonite. 
Vodena agrokemijska suspenzija u skladu sa bilo kojim od patentnih zahtjeva 1 1 6 do 8, gdje suspenzija je formulacija i neorgansko sredstva za zgušnjavanje je barem jedna vrsta odabrana iz grupe koja se sastoji od magnezij aluminij silikata i montmorilonita.
The method of claim 1, wherein the aqueous acetate or glutamate buffered G-CSF composition provided in step (a) has a volume of from 100 ml to 4 l. 
Postupak prema bilo kojem zahtjevu od 1 do 5, naznačen time, da vodeni acetat ili glutamat puferiranog G-CSF- sastava, koji je pribavljen u koraku (a), ima volumen od 100 ml do 4 [, 1 još bolje od 100 ml do 1,5 L
The present invention also contemplates a method for determining whether a subject having a cancer is a candidate for an anti-CSF-1R antibody-based cancer treatment regimen, wherein said antibody is the antibody of the present invention comprising: (1) ex vivo or in vitro determining the level of CSF-1, or IL-34, or both, in a sample of the subject, wherein the sample is selected from the group consisting of blood, serum, plasma, tumor cells and circulating tumor cells; and (2) wherein an increase in the level of CSF-1, or IL-34, or both, as compared with the level of CSF-1, or IL-34, or both, in an individual not suffering from cancer, is indicative that the subject is a candidate for the anti-CSF-1R antibody-based cancer treatment regimen. 
Postupak određivanja je li subjekt koji ima rak kandidat za režim liječenja raka na bazi protutijela protiv CSF-IR, gdje je navedeno protutijelo protutijelo u skladu s bilo kojim od patentnih zahtjeva 1-3, naznačen time što se sastoji u: određivanju razine CSF-1 ili IL-34, ili oba, ex vivo ili in vitro u uzorku iz subjekta, gdje se uzorak bira iz skupine koju čine krv, serum, plazma, tumorske stanice i tumorske stanice u cirkulaciji, gdje porast razine CSF-I, ili 11-34, ili oba, u usporedbi s razinom CSF-1, ili IL-34, ili oba, kod pojedinca koji ne boluje od raka, ukazuje da je subjekt kandidat za režim liječenja raka na bazi protutijela protiv CSF-IR.
The method according to any one of claims 5 to 9, wherein amylase is added to the textured food product after the extruder cooking step but before the additional high pressure cooking step. 
Postupak prema zahtjevu 4 ili 5, naznačen time da: da se amilaza dodaje u teksturirani prehrambeni proizvod nakon koraka kuhanja u ekstruderu, ali prije dodatnog kuhanja pod visokim tlakom.
The method of claim 1, wherein the anti-CGRP receptor monoclonal antibody is a monoclonal IgG1 or monoclonal IgG2 antibody. The method of claim 1, wherein the anti-CGRP receptor monoclonal antibody or antigen-binding fragment thereof is administered in a pharmaceutical composition comprising a buffer, a surfactant, and a stabilizing agent. 
Protutijelo anti-CGRP receptora ili njegov ulomak koji veže antigen za uporabu prema bilo kojem od patentnih zahtjeva 1 do 15, naznačeno time što se protutijelo anti-CGRP receptora ili njegov ulomak koji veže antigen daje u farmaceutskom pripravku koji sadrži pufer, surfaktant, i sredstvo za stabilizaciju.
Total Number of Cycles 
Broj međunarodne objave:
Ulipristal acetate (17a-acetoxy-11B-[4- N, N -dimethylamino-phenyl)-19-norpregna- 4, 9-diene-3, 20-dione) or any metabolite selected from the group consisting of CDB-3877, CDB-3963, CDB-3236, and CDB-4183, for use in reducing or stopping bleedings in a patient suffering from uterine fibroids according to claim 1 for a further use in preventing or treating anemia in said patient. 
Ulipristal acetat (17a-acetoksi-11B-[4-N,N-dimetilamino-fenil)-19-norpregna-4,9-dien-3,20-dion) ili bilo koji metabolit izabran iz grupe koja obuhvaća CDB-3877, CDB-3963, CDB-3236, i CDB-4183, za uporabu radi smanjenja ili zaustavljanja krvarenja u bolesnice koja boluje od uterinih fibroida prema zahtjevu 1 za daljnju uporabu u prevenciji ili liječenju anemije u te bolesnice.
The protected amine can be prepared from the properly substituted (2-mercapto-benzyl)-methyl-carbamic acid ester and the properly substituted 7-halo indole or 7-pseudohalo indole, where “halo” is either bromo or iodo and “pseudohalo” is e.g. triflate or nonaflate, as described in method 9. 
Zaštićeni amin se može pripremiti iz pravilno supstituiranog (2-merkapto-benzil)-metil-karbamski kiselog estera i pravilno supstituiranog 7-halo indola ili 7-pseudo-halo indola gdje je "halo" ili brom ili jod, a "pseudohalo" jer triflat ili nonaflat kako je to opisano u metodi 9.
Container according to claim 1, characterized in that the edge of the wall section (4) projects essentially in envelope direction (M) of the container forming a handle. 
Spremnik prema jednom od prethodnih patentnih zahtjeva, naznačen time da je dio stijenke (4) krut.
A method according to claim 5 wherein administration is via a medicament dispenser selected from a reservoir dry powder inhaler, a multi-dose dry powder inhaler or a metered dose inhaler. 
Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 4, naznačen time što se primijenjuje kroz dozator za lijek koji se bira iz skupine koju čine inhalator sa spremnikom za suhi prah, višedozni inhalator sa suhim prahom i inhalator za odmjerene doze.
Controlled release from the dosage form according to the invention is preferably achieved by embedding the active ingredient in a matrix. 
Kontrolirano oslobađanje iz oblika davanja prema izumu postiže se prvenstveno ugradnjom djelatne tvari u matricu.
Use according to any one of the preceding claims, characterized in that following addition of said 2-((1-methylpropyl)amino)ethanol to said suspension, the suspension is introduced in a unit equipped with a conductivity-based regulation device. 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time da se, nakon dodavanja navedenog 2-((1-metilpropiljaminojetanola u navedenu suspenziju, suspenzija dodaje u jedinicu opremljenu napravom za regulaciju na temelju vodljivosti.
RC1, RC2 RC3 and RC4 are each independently selected from hydrogen, methyl, ethyl, hydroxymethyl, hydroxyethyl, methoxymethyl, methoxyethyl, 2,2,2-trifluoroethyl, or 
R", R9 RS iR" su svaki nezavisno odabrani od vodika, metila, etila, hidroksimetila, hidroksietila, metoksimetila, metoksietila, 2,2,2-trifluoroetila, ili
• (b1) granulating a mixture of one or more excipient(s), the irbesartan and the wetting liquid to obtain granulate, and (b2) optionally adding further excipient(s) to the granulate to obtain a compression mixture; or 
* (b2) po izboru dodavanjem daljnjih pomoćnih tvari u granulat da bi se dobila smjesa za komprimiranje; ili * (c1) granuliranjem smjese jedne ili više pomoćnih tvari, dijela irbesartan hidroklorida i tekućine za vlaženje da bi se dobio granulat, te
A method according to claim 1 or claim 2 wherein the GPR119 agonist is a selective GPR119 agonist. 
Pripravak u skladu sa zahtjevom 1, naznačen time, da GPR119 agonist je selektivni GPR119 agonist.
In some implementations, prior to (c), the methods include an operation of computationally removing allele frequencies for polymorphisms identified has being homozygous in both the fetus and the pregnant individual. 
Postupak prema patentnom zahtjevu 1, naznačen time što nadalje sadrži, prije postupka (c), računalno uklanjanje učestalosti alela za polimorfizme koji su identificirani kao homozigotni i kod fetusa i kod trudne osobe.
The CD19xCD3 bispecific single chain antibody construct for the use of any one of claims 1 to 14, wherein the CD19xCD3 bispecific single chain antibody construct is to be administered in a daily dose of 5µg per square meter patient body surface area at the first day(s) of the infusion period followed by administration of a daily dose of 15µg per square meter patient body surface area for the remaining treatment period. 
CD19xCD3 bispecifično jednolančano protutijelo kao konstrukt namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1 do 12, naznačen time što CD19xCD3 bispecifično jednolančano protutijelo kao konstrukt treba primijeniti u dnevnoj dozi od 15 µg, 30 µg, 60 µg ili 90 µg po kvadratnom metru površine pacijentovog tijela.
The process according to claim 1, wherein step a′) is carried out in a distillation column and wherein the acetic acid distilled off in step b) is recycled to the acetic acid stream entering the distillation column. 
Postupak prema bilo kojem od zahtjeva 1-4 naznačen time što se destilirana octena kiselina u koraku b) reciklira u struju octene kiseline koja ulazi u kolonu za destilaciju vode u koraku a).
Method according to claim 1, wherein the laser energy is adapted as to provide a visible image in the second image area (20) and onto the adjacent surface (13, 14) without pyrolysis gases forming in a third image area. 
Metoda prema patentnom zahtjevu 14, pri čemu je laserska energija prilagođena kako bi stvorila vidljivu sliku u drugom slikovnom području (20) 1 za stavljanje na susjednu površinu (13, 14) bez stvaranja plinova nastalih pirolizom u trećem slikovnom području.
A composition comprising degarelix for use in the treatment of prostate cancer in a subject identified as having a cholesterol level ≥ 4 mmol/L. 
Pripravak koji sadrži degareliks za uporabo u liječenju metastatskog stadija raka prostate u subjektu koji ima osnovnu razinu seruma alkalne fosfataze (S-ALP) od 200 IU/L ili više (prije liječenja).
is selected from the group consisting of: C1-4alkyl, cyclopropylmethyl, cyclobutylmethyl and [1-(trifluoromethyl)cyclopropyl]methyl, each of which is optionally substituted with one or more substituents as allowed by valence independently selected from the group consisting of: F and hydroxy; 
R' je izabran iz grupe koja se sastoji od: Crualkil, ciklopropilmetil, ciklobutilmetil i [1-(trifluorometil) ciklopropillmetil, pri čemu je svaki izborno supstituiran sa jednim ili više supstituenata kao što je dozvoljeno valencijom nezavisno izabranim iz grupe koja se sastoji od: F i hidroksi;
said antibody or fragment does not increase human TSLP-stimulated secretion of TARC in cells expressing the TSLP-R. 
- < navedeno antitijelo ili fragment ne povećavaju izlučivanje TARC inducirano humanim TSLP u stanicama koje eksprimiraju TSLP-R.
Ar is a homocycle selected from the group of phenyl, naphthyl, acenaphthyl, tetrahydronaphthyl, each optionally substituted with 1, 2 or 3 substituents, each substituent independently selected from the group of hydroxy, halo, cyano, nitro, amino, mono- or dialkylamino, alkyl, haloalkyl, alkyloxy, haloalkyloxy, carboxyl, alkyloxycarbonyl, aminocarbonyl, morpholinyl and mono- or dialkylaminocarbonyl; 
Ar je homocikal koji je odabran iz skupine koja sadrži fenil, nafuil, acenaftil, tetrahidronaftil, svaki proizvoljno supstituiran sa 1, 2 ili 3 supstituenta, a svaki supstituent je neovisno odabran iz skupine koja sadrži hidroksi, halo, cijano, nitro, amino, mono- ili dialkilamino, alkil, haloalkil, alkiloksi, haloalkiloksi, karboksil, alkiloksikarbonil, aminokarbonil, morfolinil i mono- ili dialkilaminokarbonil;
the tissue is cardiac tissue, retinal tissue or bone tissue; 
(b) tkivo je srčano tkivo, bubrežno tkivo ili koštano tkivo;
reacting 2,2-dimethyl-1,3 dioxolane-4-carbaldehyde of formula with a vinyl Grignard reagent, to obtain a compound of formula IIa in the form of diastereomeric mixture (S,R+R,R) 
"a dai mA S vinil Grignardovim reagensom, da bi se dobio spoj formule Ila u obliku dijastereoizomerne smjese (S, R+R,
In a fourth class of this embodiment, about 50% to about 100% by weight of the crystalline monohydrate is present in the drug substance. 
U četvrtoj klasi ove implementacije, oko 50% do oko 100% težinski kristalnog monohidrataje nazočno u supstanci lijeka.
Figure 9 is a diagram showing the connection of the receiver, used in the present invention, to the anchor winch of the boat; 
Slika 9 je dijagram koji prikazuje spoj prijemnika, koji se koristi u opisanom izumu, i sidrenog vitla plovila;
The concept of the invention is to replace or at least considerably reduce the amount of evaporating solvents in thermally cured liquid coatings by using a fatty acid or fatty acid derivative as reactive diluents. 
Zamisao izuma je da se u tekućim premazima, koji se otvrdnjavaju pomoću topline, zamijeni ili barem značajno smanji količinu hlapljivog otapala i to upotrebom masne kiseline ili derivata masne kiseline kao reaktivnog sredstva za razrjeđivanje.
The compound according to claim 2 wherein A is selected from the group consisting of 
Rc i Rp su neovisno odabrani iz skupine koja se sastoji od vodika 1 alkila,
Process according to claim 1, wherein the esters of fatty acid are distilled at a pressure lower than 0.1 mbar and a temperature less than 150° C. 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se esteri masnih kiselina destiliraju pod tlakom ispod 0,1 mbar (10 Pa) 1 na temperaturi ispod 150%C.
More specifically, according to the invention, the lipophilic extract of Echinacea angustifolia will be prepared by extraction with carbon dioxide under supercritical conditions as reported in patent EP 464298 filed by the applicant. 
PATENTNI ZAHTJEVI Pripravak, naznačen time da sadrži: a) lipofilni ekstrakt Zingiber officinale, te b) lipofilni ekstrakt Echinacea angustifolia, koji se dobivaju ekstrakcijom s ugljičnim dioksidom pri superkritičnim uvjetima.
hypertension before, during, or after surgery; 
hipertenzija prije, za vrijeme, ili nakon operacije;
• Immunosuppressive agents 
imunosupresivna sredstva,